TrialClinical and translational science2024

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study.

Kyoko Miyamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.